Vitro Biopharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Oct 31, 2025	FY2024 12 months to Oct 31, 2024	FY2023 12 months to Oct 31, 2023	FY2015 12 months to Oct 31, 2015	FY2014 12 months to Oct 31, 2014
Operating Activities
Consolidated Net Loss
Adjustment to Reconcile Net Loss:
Other Project Income, Net
Gain on Forgiveness of Debt
Unrealized Gain on Derivative/Warrant Liability
Depreciation Expense
Amortization Expense
Bad Debt Expense
Depreciation and amortization
Impairment of deferred patent costs
Impairment Expense
Amortization of Operating Lease – ROU Asset
Accretion of Debt Discount
Stock Based Compensation
Common stock issued for consulting services

Increase in accounts receivable, inventories, prepaid expenses and deposits
Common Stock Issued for Services
Pre-funded Warrants issued for Services
(Gain) Loss on Extinguishment of Debt
Write-off of Offering Costs
Changes in Assets and Liabilities
Increase in accounts receivable, inventories, prepaid expenses and deposits
Increase in accounts payable and accrued expenses
Accounts Receivable
Accounts Receivable – Related Party
Inventory
Prepaid Expenses
Prepaid Project Costs
Accounts Payable
Deferred Revenue, Net
Accounts Payable – Related Party
Operating Lease Obligation
Accrued Liabilities
Accrued Liabilities – Related Party
Accrued Interest
Accrued Interest – Related Parties
Other Assets
Net Cash Used in Operating Activities
Investing Activities
Purchases of equipment
Payments for patents and deferred costs
Acquisition of Property and Equipment
Patent Costs
Net Cash Used in Investing Activities

Financing Activities
Proceeds from advances from officer
Deferred Offering Costs
Issuance of 2024 Senior Secured Convertible Notes Payable
Issuance of 2023 Series Convertible Notes Payable - Stock Settled
Issuance of 2023 Series B Convertible Notes Payable – Stock Settled
Issuance of Series A-1 Convertible Preferred Stock
Issuance of 2024 Series Senior Secured Convertible Notes Payable – Stock Settled
Issuance of 2025 Series Senior Secured Convertible Notes Payable – Stock Settled
Payment of 2024 Senior Secured Convertible Notes Payable
Payment of 2021 Series Convertible Note Payable – Related Party
Capital Lease Principal Payments
Payments on Revolving Line of Credit
Net Cash Provided by Financing Activities
Net change in cash
Cash, beginning of year
Cash, end of period
Cash paid for Interest

Total Cash Provided During the Period
Beginning Cash Balance
Ending Cash Balance
Cash Paid for Interest
Cash Paid for Income Taxes
Common stock issued to directors for services
Common stock issued for consulting services
Common stock issued upon conversion of accounts payable
Supplemental Schedule of Non-Cash Financing Activities:
Common stock issued to directors for services
Common stock issued for services
Purchase of equipment under capital lease
Premium on issuance of 2023 Series Notes Payable - Stock Settled
Derivative/Warrant Liability on 2023 Series Notes Payable
Discount on Derivative/Warrant Liability on 2023 Series Notes Payable
Premium on issuance of 2024 Senior Secured Convertible Notes
Derivative/Warrant Liability on 2024 Senior Secured Convertible Notes
Discount on Derivative/Warrant Liability on 2024 Senior Secured Convertible Notes
Premium on issuance of 2023 Series and 2023 B Series Notes Payable - Stock Settled
Derivative/Warrant Liability on 2023 Series and 2023 B Series Notes Payable
Discount on Derivative/Warrant Liability on 2023 Series and 2023 B Series Notes Payable
Forgiveness of Accrued Liabilities – Related Party
Premium on issuance of 2023 Series B Notes Payable – Stock Settled
Derivative/Warrant Liability on 2023 Series B Notes Payable
Discount on Derivative/Warrant Liability on 2023 Series B Notes Payable
Deferred Offering Costs Recorded as Accounts Payable
Right of Use Asset and Operating Lease Obligation Recognized under ASC Topic 842
Derivative/Warrant Liability on 2025 Series Senior Secured Notes Payable
Discount on Derivative/Warrant Liability on 2025 Series Senior Secured Notes Payable
Derivative/Warrant Liability on 2024 Series Senior Secured Notes Payable
Discount on Derivative/Warrant Liability on 2024 Series Senior Secured Notes Payable

Comments